Over the past decade, the pharmaceutical industry has experienced rapid growth in using new and advanced ideas. Prefilled syringes have become a popular method of drug delivery to treat an increasing number of patients suffering from chronic diseases, cancers, or autoimmune diseases due to increased safety, ease in usage, convenience, accuracy in clinical use, and the ability for self-injections. Moreover, they gained strong acceptance for chronic conditions requiring repeated medication administration.²^,³ A prefilled syringe (PFS) is filled with one or more active medicines at the required concentration and volume and correctly labelled before it enters the final clinical area, where it can be administered immediately without further preparation.

One of the recent reports, published in November 2024 by Fortune Business Insights, shows the global prefilled syringe market is expected to continue experiencing exceptional growth over the next eight years. The global prefilled syringes market size was $7.91 billion in 2023 and is projected to grow from $8.70 billion in 2024 to $20.62 billion by 2032, exhibiting a CAGR of 11.4% during the forecast period 2024–2032. Europe dominated the prefilled syringe market with a market share of 40.33% in 2023. North America is likely to hold the second-largest market share after Europe, owing to the rise in several chronic diseases, such as diabetes and rheumatoid arthritis. These diseases are likely to enhance the demand for prolonged drug administration at an accurate dosage.⁴

In hospital settings, where decisions must be taken more quickly or under stress (i.e., operating theatres, during urgent interventions, emergency department, ICUs), medication error rates in preparing injectable drugs from vials and ampoules are substantially higher. These errors can result from standard human factors and resource constraints, leading to Adverse Drug Events (ADEs). Such ADEs can substantially increase hospital operating costs. Several literature reports suggest that PFS can ensure sterility and help reduce medication errors associated with mislabelling, dosing errors, and related expenses. It’s also reported that usage of PFS can also benefit drug/disposables/packaging waste reduction and medication preparation time reduction by more than 50%.